Articles tagged with Amyotrophic Lateral Sclerosis
A double-blind randomized trial found no benefit of lithium in slowing ALS progression, contrary to initial promising results from a small pilot study. The trial involved 84 patients with ALS and showed that lithium plus riluzole did not slow disease progression more than riluzole alone.
Researchers have discovered a genetic mutation associated with motor neurone disease that causes proteins to clump together in motor neurones, leading to their death. The new finding provides strong evidence for protein aggregation as the underlying cause of MND.
A new ALS drug, talampanel, has shown some ability to slow the loss of major daily life activities such as speaking, walking and dressing. The study found that talampanel slowed progression of ALS by 30 percent, according to the ALS Functional Rating Scale.
Researchers have discovered that high levels of lead can slow the progression of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease. This finding suggests that lead may activate a novel pathway able to reduce neuroinflammation and slow neurodegeneration in ALS patients.
A new study published in Neurology suggests that smoking is an established risk factor for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. The findings support the link between environmental factors and ALS occurrence, highlighting potential avenues for treatment.
A team of researchers led by Salk Institute scientist Sam Pfaff aims to develop a novel stem-cell derived therapy for Amyotrophic Lateral Sclerosis (ALS). The project focuses on growing clinical-grade astrocyte precursor cells and testing their efficacy and safety.
Researchers found that administering APC and its analogs slowed disease progression and extended survival in mutant SOD1-expressing mice. These compounds worked by decreasing SOD1 expression in brain cells, indicating a potential neuroprotective effect of APC in mouse models of inherited ALS.
Researchers found that administration of APC protein slowed disease progression and extended survival in mice with inherited ALS. The study suggests activating APC might benefit patients with inherited and possibly sporadic ALS, but warns of potential risks.
Scientists have discovered a compound that dramatically slows the progression of amyotrophic lateral sclerosis (ALS) in mice by extending their lifespan by 25 percent and reducing muscle wasting. The enzyme APC has been shown to protect neurons from cell death caused by SOD1 mutations, which are linked to most sporadic cases of ALS.
The new guidelines from the American Academy of Neurology identify riluzole as a treatment that can slow disease progression in ALS patients. Using an assisted-breathing device is also expected to increase life expectancy and quality of life for these patients.
New guidelines for treating Lou Gehrig's disease recommend the use of riluzole, assisted-breathing devices and PEG feeding tubes to increase longevity and quality of life. Dr. John England and his team analyzed research findings to provide specific, evidence-based recommendations for ALS care.
Premature aging of the immune system has been linked to amyotrophic lateral sclerosis (ALS), according to research. Studies found that patients with ALS have reduced CD4+ T cells and thymic malfunction, contributing to disease progression.
Researchers at Michigan Technological University have identified three genes linked to sporadic ALS, a type of neuromuscular disorder. The discovery provides valuable insights into the genetic basis of the disease and may lead to the development of new treatments or a potential cure.
Researchers found that protein aggregates, previously thought to cause ALS, actually appear later on, increasing in number before symptoms appear. This discovery suggests a larger therapeutic window to treat the disease if diagnosed early.
A genetic variant in the KIFAP3 gene has been linked to a significant increase in survival time for patients with amyotrophic lateral sclerosis (ALS). The variant, found in over 1,800 individuals with ALS and nearly 2,200 unaffected controls, is associated with improved motor function and increased survival by 40-50 percent.
Scientists at the University of Edinburgh have discovered that zebrafish can produce motor neurones after spinal cord damage, offering a potential stem cell treatment for humans. Researchers are now screening small molecules to find drugs that could kick-start motor neurone regeneration.
Researchers identified key elements of dynein's structure and its winch-like mechanism, correcting some mistaken ideas. Dynein is responsible for transporting molecular cargo within cells, powering movement of sperm and eggs, and helping cells divide.
High levels of specific proteins in spinal fluid may signal the onset of Lou Gehrig's disease. Researchers developed a diagnostic kit using these biomarkers, achieving 92% accuracy in identifying ALS patients.
A recent study has genetically linked Lou Gehrig's disease in humans to a similar disease in dogs called degenerative myelopathy. The researchers discovered that dogs with this disease have the same genetic mutation as humans with ALS, paving the way for using them as animal models to help identify therapeutic interventions.
A genetic modification has prolonged the life of mice with amyotrophic lateral sclerosis (ALS) by boosting antioxidant production. The discovery offers new hope for treating ALS and other neurodegenerative diseases.
Scientists have identified a gene in mice that plays a central role in the development of corticospinal neurons, which degenerate in patients with ALS. The discovery provides insight into how stem cells in the brain become specific types of neurons.
A Brandeis study finds that mutated protein superoxide dismutase leads to toxic levels of the protein in motor neurons, causing cell death in ALS patients. The research aims to develop drugs targeting key proteins to prevent aggregation and treat the disease.
Researchers found that SOD1 protein stability and aggregation propensity are key factors in predicting patient survival. Mutations that increase stickiness and decrease stability of the protein correlate with reduced survival times.
A study by Duke University researchers found a possible geographical pattern for ALS cases among 1991 Gulf War veterans, with some areas of service showing an elevated risk. The research uses GIS analysis to identify potential environmental exposures that may be associated with the disease.
A new study by UC researchers suggests that cases of Amyotrophic Lateral Sclerosis (ALS) among soldiers who served in the first Persian Gulf War were caused by specific events, with a declining risk after 1996.
Researchers at Montreal Neurological Institute discovered a critical gene, Runx1, that regulates motor neuron development and maintenance. This finding holds promise for understanding and treating neurodegenerative diseases such as ALS.
Researchers found a significant link between ALS and formaldehyde exposure, with longer-term exposure increasing the risk. Formaldehyde is used in various household products and has not been previously linked to ALS.
Research finds that leaky blood vessels in mice with ALS mutations expose neurons to toxic substances, contributing to disease progression. The study opens a new front in understanding ALS, a debilitating disease that affects motor neurons.
A team of Canadian and French researchers has identified the TDP-43 gene as a significant cause of ALS (sporadic amyotrophic lateral sclerosis), a neuromuscular disorder affecting motor neurons. The study, published in Nature Genetics, found that up to five percent of ALS patients have genetic mutations in this gene.
Researchers have identified a mutation in the TDP-43 gene linked to inherited amyotrophic lateral sclerosis (ALS) and suggest it may also play a role in common dementia. The study's findings could provide new insights into understanding ALS and developing treatments.
In a breakthrough study, targeting astrocytes in mice with amyotrophic lateral sclerosis (ALS) doubles the lifespan of affected animals. This finding suggests that astrocytes, support cells essential for neuronal function, may be viable targets to slow disease progression and extend life expectancy.
A study published in PLOS ONE found that mice with amyotrophic lateral sclerosis (ALS) have a compromised blood-spinal cord barrier, leading to vascular leakage and potential mechanisms for motor neuron damage. Researchers hope this finding will lead to the development of new treatments targeting the barrier's repair.
Researchers have found that mutated forms of the angiogenin gene are toxic to motor neurons and affect their ability to grow and extend. Targeting these faulty molecules may help maintain healthy neurons and prevent disease progression.
Scientists found that inhibiting Nox1 and Nox2 genes can slow down ALS progression in mice, leading to improved survival rates. The study suggests developing drugs targeting the Nox pathway could be beneficial for individuals with ALS.
Motor neurone disease is a degenerative disorder that causes loss of basic motor functions, with symptoms including bulbar-onset, cervical-onset, and lumbar-onset patients. The disease has been reported in certain populations, such as the Chamorro population on Guam, and may be linked to genetic and environmental factors.
Researchers at Johns Hopkins have shown that transplanting human stem cells into spinal cords of rats bred to duplicate Lou Gehrig's disease delays the start of nerve cell damage typical of the disease and slightly prolongs life. The transplanted stem cells develop into nerve cells that make substantial connections with existing nerves.
A new study reveals a common pathological process between frontotemporal dementia and amyotrophic lateral sclerosis (ALS), with misfolded protein TDP-43 identified as a key component. This discovery may lead to a better understanding of these devastating neurological diseases.
Researchers at Oregon State University have developed a new technique to visualize and measure superoxide in animal cells, offering a breakthrough in understanding degenerative diseases such as Lou Gehrig's Disease, heart disease, diabetes, and aging. The discovery could significantly speed up research on these conditions.
Researchers delivered antisense oligonucleotides through cerebrospinal fluid to treat neurodegenerative diseases like ALS. The therapy effectively modulated protein levels and slowed disease progression in rats.
Researchers develop a novel approach to treat amyotrophic lateral sclerosis (ALS) by delivering an antisense oligonucleotide drug directly to the brain and spinal cord. The treatment slows disease progression by silencing mutant proteins that cause the disease, offering new hope for patients.
Researchers found strong association between PON2-PON3 gene cluster polymorphisms and sporadic ALS, a complex neurodegenerative disorder. Gene variations may help elucidate the cause of sporadic ALS, potentially leading to specific treatments.
Researchers found that a high-caloric ketogenic diet slowed ALS progression in mice by promoting mitochondrial energy production and membrane stabilization. The study suggests that dietary interventions may offer new therapeutic options for ALS patients.
U of MN researchers identified the specific mutation causing Spinocerebellar ataxia type 5 (SCA5), a dominant gene disorder. The discovery enables genetic testing for patients at risk, providing improved diagnoses and insight into neurodegenerative diseases.
The study found that T cells recognize brain proteins and recruit resident immune cells to fight off toxic substances, enabling neurogenic regions like the hippocampus to form new nerve cells. This process is linked to local immune activity and may play a role in maintaining learning and memory abilities in adulthood.
A new way to stimulate the brain to release antioxidants has been discovered by researchers, potentially treating ischemic stroke, multiple sclerosis, and neurodegenerative disorders. The NEPPs compound activates the Keap1/Nrf2 pathway to regulate antioxidant production, offering a promising approach for neuroprotection.
Researchers found that exercise combined with gene therapy significantly extended the lifespan of mice with ALS, averaging 210 days, compared to 120 days in untreated mice. Early exercise initiation also improved outcomes, suggesting a potential strategy for slowing disease progression.
The Squid Genome Project aims to identify genes in squid that are essential for understanding debilitating neurological diseases. Researchers hope that this information will aid in the development of new treatments and therapies.
The AAN Foundation and ALS Association are partnering to provide funding for a Clinician Scientist Development Award in support of ALS research. The award aims to prioritize promising compounds for clinical trials, bringing hope to patients suffering from this debilitating disease.
Researchers found that riluzole, a glutamate modulating agent, reduced symptoms in 35% of patients with OCD. The study suggests that riluzole may represent a novel treatment intervention for certain anxiety and mood disorders.
Researchers at Johns Hopkins Medicine have identified two proteins that help replace calcium-allowing channels with ones that keep calcium out, potentially protecting nerve cells from Lou Gehrig's disease. The discovery may lead to new ways to harness the channel-changing ability in other brain cells.
Researchers have found that 47% of ALS patients exhibit reverse transcriptase activity, suggesting a potential link to retroviruses. Further study is needed to determine if this reflects activation of an endogenous retrovirus or infection with a novel exogenous retrovirus.
A recent study published in Neurology found no significant association between increased physical activity and the risk of developing amyotrophic lateral sclerosis (ALS). However, it was discovered that higher leisure time physical activities before age 25 resulted in an earlier onset of the disease by seven years.
A large multi-center clinical trial is planned to test the safety and efficacy of antibiotics in treating ALS. Daily injections of ceftriaxone delayed nerve damage and extended survival by 10 days in mice with a Lou Gehrig's disease model.
Researchers transplanted adult olfactory bulb stem cells into genetically engineered mice with ALS, showing a significant delay in disease symptoms and improved functional outcomes. The study suggests these stem cells may hold potential for treating ALS, but further laboratory work is needed.
Researchers have used human spinal cord cells to delay ALS symptoms in rats by 11 days. The study's findings suggest that neuronal stem cells may hold promise for treating conditions caused by separation within the nervous system.
Scientists have found that a longevity protein called SIRT1 delays the breakdown of axons in nerve cells, potentially slowing neurodegenerative diseases. The discovery opens new avenues for treating Parkinson's disease, Alzheimer's disease, and other disorders.
Mitochondrial damage is a key factor in Lou Gehrig's disease, causing cells to die. The study reveals that mutant SOD1 protein clogs the transport system of mitochondria in muscle-controlling nerve cells.
Researchers have discovered biomarkers for ALS in cerebrospinal fluid, which could enable rapid diagnosis and prompt treatment. These biomarkers have high sensitivity and specificity, and may be used to monitor drug effectiveness in clinical trials.
A new gene mutation has been discovered for a rare form of inherited paralysis called hereditary spastic paraplegia. This breakthrough could lead to improved diagnosis and potential treatments for the condition, which affects around 20,000 Americans.
A study published in Neurology reveals that Gulf War veterans under 45 have developed ALS, a neurodegenerative disorder, at an alarming rate. The Department of Veterans Affairs confirms the findings using a different method, raising questions about environmental exposures during the war and potential links to Gulf War syndrome.